Article

A novel serum glucocorticoid regulated kinase 1 inhibitor improves cardiac structure and function in heart failure

2025-11-10

Abstract excerpt

<title>Abstract</title> <p>Despite the advent of transformative guideline-directed therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide, underscoring an urgent need for novel therapies. Clinical benefits of contemporary interventions (sodium-glucose co-transporter-2 inhibitors, SGLT2i) in HF suggest the importance of metabolic modulation to complement classical neurohormo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e9db787f-959c-5836-bddf-45d64a11353a
DOI: 10.21203/rs.3.rs-7539711/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A novel serum glucocorticoid regulated kinase 1 inhibitor improves cardiac structure and function in heart failureDOI 10.21203/rs.3.rs-7539711/v1Read

Therapeutic potential of serum and glucocorticoid inducible kinase inhibition.Semantic proximity Read

Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseasesSemantic proximity Read

Serum and glucocorticoid inducible kinase, metabolic syndrome, inflammation, and tumor growth.Semantic proximity Read

Sodium-glucose co-transporter 2 Inhibitors Act Independently of <i>SGLT2</i> to Confer Benefit for Heart Failure with Reduced Ejection Fraction in MiceSemantic proximity Read

Glucocorticoid chrono-pharmacology unveils novel targets for the cardiomyocyte-specific GR-KLF15 axis in cardiac glucose metabolismSemantic proximity Read

Constitutive expression of cardiomyocyte Klf9 precipitates metabolic dysfunction and spontaneous heart failureSemantic proximity Read

G protein-coupled receptor kinases in normal and failing myocardium.Semantic proximity Read

Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEFSemantic proximity Read

Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC TherapySemantic proximity Read

SGK1, a Critical Regulator of Immune Modulation and Fibrosis and a Potential Therapeutic Target in Chronic Graft-Versus-Host DiseaseSemantic proximity Read

Salt-inducible kinase inhibition promotes weight loss and improves the diastolic function of obesity-related heart failure with preserved ejection fraction in miceSemantic proximity Read

Pharmacological inhibition of 11ßhydroxysteroid dehydrogenase type 1 after myocardial infarction targets extracellular matrix processing and preserves cardiac function in a translational mini-pig modelSemantic proximity Read